All the most promising drugs approved by FDA in 2017 and their future potential In 2017, the Center for Drug Evaluation and Research (CDER) of FDA approved 46 novel drugs. … Continue Reading Top 31 Most Promising Drugs 2018
Τα αποτελέσματα δύο σημαντικών μελετών αναφορικά με τη θεραπεία της αρτηριακής υπέρτασης με τη μέθοδο της κατάλυσης των νεφρικών αρτηριών, ανακοινώθηκαν στο συνέδριο επεμβατικής καρδιολογίας στο Παρίσι, στο EuroPCR. Το … Continue Reading Θεραπευτική λύση για εκατομμύρια υπερτασικούς με τη συμβολή Ελλήνων επιστημόνων
By recasting impotence as “erectile dysfunction,” Pfizer and its marketing partners were able to traditional attitudes. When Pfizer launched Viagra, in 1998, it did so with eyes wide open … Continue Reading 7 ways Viagra changed how drugs are marketed
SAN JOSE, Calif. – Although CAR-T therapies have only been approved for the treatment of B-cell blood cancers, tiny ITUS believes it is on track to develop a CAR-T treatment … Continue Reading ITUS Pushes CAR-T Program for Solid Tumors, Develops Early Cancer Detection Platform
Credit: Pixabay. Researchers at the University of Oxford have proposed an evolutionary framework to understand why microbes living in the gut affect the brain and behaviour, published in Nature Reviews … Continue Reading Can Microbes Manipulate Our Minds?
The FDA has approved the use of Novartis’ CAR-T therapy Kymriah in adult patients with diffuse large B-cell lymphoma (DLBCL), an indication where it will compete with Gilead’s Yescarta. Kymriah … Continue Reading Novartis and Gilead’s CAR-T Therapies Now Compete for the Same Cancer Patients
Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a … Continue Reading The First CAR-T Therapy Is Not Living Up to Commercial Expectations
Today is the World Blood Cancer Day, an event to show solidarity to patients and raise awareness for the need of better therapies to treat these cancers – which are … Continue Reading It’s Blood Cancer Day, how is Biotech fixing it?
It sounds like a lot of fun, but DNA legos are serious: they represent the core concept of synthetic biology, a field with the potential to solve major issues in … Continue Reading Building Life from DNA Legos, a Review of Synthetic Biology
Brain diseases are hard to treat, but biotechs are harnessing a variety of techniques, including immunotherapy and gene therapy, to target neurodegenerative disorders. When Eli Lilly announced that solanezumab, a … Continue Reading Biologicals on the Brain: Biotech in Neurodegenerative Disease
Juno’s JCAR015 study came to a halt for the second time this year after two more patient deaths. But despite the bad news, hopes for CAR-T therapies remain high. Juno … Continue Reading What do the CAR-T Patient Deaths Mean for the Future of the Field?
With 422 million people suffering from diabetes, the disease has become an epidemic. There’s still no cure and medicine is struggling to provide an efficient solution. However, from needle-free glucose … Continue Reading Can Biotech Stop the Diabetes Epidemic? Reviewing the Hottest Technology
Genome sequencing has taken off in recent years, and large-scale projects are leading the way. This review looks at efforts around the world. Gene sequencing has proved its usefulness as … Continue Reading The Past, Present and Future of Genome Sequencing
With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis. Roche may be the first, but others in the biotech community are also working hard … Continue Reading How Biotech is Mastering Multiple Sclerosis: A Review
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of immuno-oncology. What’s it all about? Jean-Christophe Marcoux “NASH is a well-recognized health emergency,” says Jean-Christophe … Continue Reading Not to be Underestimated: What’s the Hype around NASH?
Just 2% of experimental pain treatments clear Phase II. Why is this challenge so great, and which biotechs are gunning for Phase III and beyond? Dating back at least to … Continue Reading A Painful Case: How Biotech is trying to Break Through in Analgesia